AstraZeneca PLC's (LSE:AZN) Truqap (capivasertib) has shown promising results in a trial for aggressive prostate cancer, improving progression-free survival when combined with standard therapies.
The phase III CAPItello-281 trial tested Truqap with abiraterone and androgen deprivation therapy (ADT) against a placebo combination in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, a form of the disease associated with poor outcomes.
The trial found a significant improvement in delaying disease progression on scans.
While overall survival data are still being collected, early results suggest a potential survival benefit.
Prostate cancer is the second most common cancer in men worldwide and has a high death rate.
Patients with PTEN-deficient tumours face worse outcomes, making this new approach significant.
Experts, including trial investigator Dr Karim Fizazi, hailed the results as progress for patients with limited options.
AstraZeneca highlighted the potential of targeting disease drivers to improve current treatments. Safety findings matched with expectations.